Quince Therapeutics (QNCX) Expected to Announce Earnings on Monday

Quince Therapeutics (NASDAQ:QNCX) will likely be issuing its quarterly earnings data on Monday, March 24th. Analysts expect the company to announce earnings of ($0.18) per share for the quarter.

Quince Therapeutics Trading Up 0.7 %

QNCX opened at $1.38 on Friday. The firm has a market cap of $60.72 million, a P/E ratio of -1.11 and a beta of 0.71. Quince Therapeutics has a 12 month low of $0.51 and a 12 month high of $2.45. The company has a current ratio of 9.53, a quick ratio of 9.53 and a debt-to-equity ratio of 0.33. The stock has a 50-day moving average of $1.50 and a 200 day moving average of $1.42.

Wall Street Analyst Weigh In

QNCX has been the subject of several recent research reports. Brookline Capital Management initiated coverage on Quince Therapeutics in a research report on Wednesday, December 18th. They issued a “buy” rating and a $9.00 price target for the company. D. Boral Capital reissued a “buy” rating and issued a $12.00 price objective on shares of Quince Therapeutics in a research note on Wednesday, February 5th. Four equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $9.50.

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.